With all the focus on the stellar launch of Regeneron's
One of those drugs, REGN727, which Sanofi calls SAR236553, is ready to hit phase 3 trials on the back of solid phase 2 data.
The drug targets a protein called PCSK9, which promotes the degradation of the LDL receptors that remove the bad cholesterol from the blood. Inhibiting PCSK9 increases the receptors, which decreases the cholesterol levels as evidenced by the 28.9% to 67.9% reduction in LDL cholesterol compared with a 10.7% reduction in patients receiving placebo.
Those are some fairly impressive numbers considering the patients have familial hypercholesterolemia, a genetic mutation that causes extremely high cholesterol levels that couldn't be controlled by statins with or without Merck's
REGN727 looks good, but it will have competition. Amgen
Regeneron and Sanofi are ahead of the other drugs attacking PSCK9, but they'll have to deal with Isis Pharmaceuticals
Those results should come out before phase 3 data on REGN727 is available, giving the drug an efficacy/safety target to reach if Regeneron is going to have another hit on its hands.
The cholesterol drug market is huge, but Fool analysts have found a larger one. Find out what it is and how to profit from it in our free report, "The Next Trillion-Dollar Revolution." Get your free copy.
Fool contributor Brian Orelli holds no position in any company mentioned. Check out his holdings and a short bio. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.
More from The Motley Fool
This Is Why Alnylam Pharmaceuticals Soared 249% in 2017
It was a breakout year for the clinical-stage biotech.
3 Top Value Stocks to Buy in 2018
Express Scripts Holding Company, Horizon Pharma plc, and Sanofi plc are three cheap stocks worth considering in 2018.
Will This Drug Kick-Start Regeneron Pharmaceuticals Shares?
An immuno-oncology drug that's in the works could generate significant revenue growth someday.